Claims for Patent: 8,865,710

Summary for Patent: 8,865,710

Title:	Methods of treating proliferative diseases
Abstract:	Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients, including a specific patient population. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided.
Inventor(s):	Robert E. Corringham, Patrick B. O'Donnell, Joyce K. James
Assignee:	Ambit Bioscience Corp
Application Number:	US13/320,217
Patent Claims:	1. A spray-dried pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, and hydroxypropyl-β-cyclodextrin. 2. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable salt is a dihydrochloride salt. 3. The pharmaceutical composition of claim 1, wherein the solvate is a methanol solvate. 4. The pharmaceutical composition of claim 1 comprising the pharmaceutically acceptable salt of compound of Formula I and hydroxypropyl-β-cyclodextrin in a ratio of about 1:10 based on weight. 5. The pharmaceutical composition of claim 1, wherein the composition is formulated for single dose administration. 6. The pharmaceutical composition of claim 1, wherein the composition is formulated for oral administration.